188 related articles for article (PubMed ID: 22086161)
21. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.
Burkhardt UE; Hainz U; Stevenson K; Goldstein NR; Pasek M; Naito M; Wu D; Ho VT; Alonso A; Hammond NN; Wong J; Sievers QL; Brusic A; McDonough SM; Zeng W; Perrin A; Brown JR; Canning CM; Koreth J; Cutler C; Armand P; Neuberg D; Lee JS; Antin JH; Mulligan RC; Sasada T; Ritz J; Soiffer RJ; Dranoff G; Alyea EP; Wu CJ
J Clin Invest; 2013 Sep; 123(9):3756-65. PubMed ID: 23912587
[TBL] [Abstract][Full Text] [Related]
22. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response.
Hus I; Schmitt M; Tabarkiewicz J; Radej S; Wojas K; Bojarska-Junak A; Schmitt A; Giannopoulos K; Dmoszyńska A; Roliński J
Leukemia; 2008 May; 22(5):1007-17. PubMed ID: 18323802
[TBL] [Abstract][Full Text] [Related]
23. Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate.
Goddard RV; Prentice AG; Copplestone JA; Kaminski ER
Clin Exp Immunol; 2001 Oct; 126(1):16-28. PubMed ID: 11678895
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF.
Podaza E; Carri I; Aris M; von Euw E; Bravo AI; Blanco P; Ortiz Wilczyñski JM; Koile D; Yankilevich P; Nielsen M; Mordoh J; Barrio MM
Front Immunol; 2020; 11():1147. PubMed ID: 32582212
[TBL] [Abstract][Full Text] [Related]
25. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.
Oosterwijk-Wakka JC; Tiemessen DM; Bleumer I; de Vries IJ; Jongmans W; Adema GJ; Debruyne FM; de Mulder PH; Oosterwijk E; Mulders PF
J Immunother; 2002; 25(6):500-8. PubMed ID: 12439347
[TBL] [Abstract][Full Text] [Related]
26. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
Pilla L; Patuzzo R; Rivoltini L; Maio M; Pennacchioli E; Lamaj E; Maurichi A; Massarut S; Marchianò A; Santantonio C; Tosi D; Arienti F; Cova A; Sovena G; Piris A; Nonaka D; Bersani I; Di Florio A; Luigi M; Srivastava PK; Hoos A; Santinami M; Parmiani G
Cancer Immunol Immunother; 2006 Aug; 55(8):958-68. PubMed ID: 16215718
[TBL] [Abstract][Full Text] [Related]
27. Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern.
Rezvany MR; Jeddi-Tehrani M; Biberfeld P; Söderlund J; Mellstedt H; Osterborg A; Rabbani H
Br J Haematol; 2001 Nov; 115(2):263-71. PubMed ID: 11703320
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.
Baek S; Kim CS; Kim SB; Kim YM; Kwon SW; Kim Y; Kim H; Lee H
J Transl Med; 2011 Oct; 9():178. PubMed ID: 22013914
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cells generated in the presence of granulocyte-macrophage colony-stimulating factor and IFN-alpha are potent inducers of HIV-specific CD8 T cells.
Carbonneil C; Aouba A; Burgard M; Cardinaud S; Rouzioux C; Langlade-Demoyen P; Weiss L
AIDS; 2003 Aug; 17(12):1731-40. PubMed ID: 12891059
[TBL] [Abstract][Full Text] [Related]
30. Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity.
Safdar A; Rodriguez GH; Rueda AM; Wierda WG; Ferrajoli A; Musher DM; O'Brien S; Koller CA; Bodey GP; Keating MJ
Cancer; 2008 Jul; 113(2):383-7. PubMed ID: 18470901
[TBL] [Abstract][Full Text] [Related]
31. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer.
Meidenbauer N; Harris DT; Spitler LE; Whiteside TL
Prostate; 2000 May; 43(2):88-100. PubMed ID: 10754524
[TBL] [Abstract][Full Text] [Related]
32. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.
Simons JW; Jaffee EM; Weber CE; Levitsky HI; Nelson WG; Carducci MA; Lazenby AJ; Cohen LK; Finn CC; Clift SM; Hauda KM; Beck LA; Leiferman KM; Owens AH; Piantadosi S; Dranoff G; Mulligan RC; Pardoll DM; Marshall FF
Cancer Res; 1997 Apr; 57(8):1537-46. PubMed ID: 9108457
[TBL] [Abstract][Full Text] [Related]
33. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen.
Smithers M; O'Connell K; MacFadyen S; Chambers M; Greenwood K; Boyce A; Abdul-Jabbar I; Barker K; Grimmett K; Walpole E; Thomas R
Cancer Immunol Immunother; 2003 Jan; 52(1):41-52. PubMed ID: 12536239
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy with irradiated autologous leukemic cells in patients with B-CLL in early stages.
Hus I; Kawiak J; Tabarkiewicz J; Radej S; Hoser G; Bojarska-Junak A; Schmitt M; Giannopoulos K; Dmoszynska A; Rolinski J
Oncol Rep; 2008 Aug; 20(2):443-51. PubMed ID: 18636210
[TBL] [Abstract][Full Text] [Related]
35. Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors.
Kokhaei P; Adamson L; Palma M; Osterborg A; Pisa P; Choudhury A; Mellstedt H
Cytotherapy; 2006; 8(4):318-26. PubMed ID: 16923607
[TBL] [Abstract][Full Text] [Related]
36. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.
Rezvani K; Yong AS; Mielke S; Jafarpour B; Savani BN; Le RQ; Eniafe R; Musse L; Boss C; Kurlander R; Barrett AJ
Haematologica; 2011 Mar; 96(3):432-40. PubMed ID: 21134985
[TBL] [Abstract][Full Text] [Related]
37. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.
Avigan DE; Vasir B; George DJ; Oh WK; Atkins MB; McDermott DF; Kantoff PW; Figlin RA; Vasconcelles MJ; Xu Y; Kufe D; Bukowski RM
J Immunother; 2007 Oct; 30(7):749-61. PubMed ID: 17893567
[TBL] [Abstract][Full Text] [Related]
38. Generation of in vitro B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotic tumor lysate.
Suresh K; Fraser G; Scheid E; Leber B; Gauldie J; Foley R
Leuk Lymphoma; 2006 Feb; 47(2):297-306. PubMed ID: 16321861
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.
Meneveau MO; Petroni GR; Salerno EP; Lynch KT; Smolkin M; Woodson E; Chianese-Bullock KA; Olson WC; Deacon D; Patterson JW; Grosh WW; Slingluff CL
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035112
[TBL] [Abstract][Full Text] [Related]
40. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.
Salcedo M; Bercovici N; Taylor R; Vereecken P; Massicard S; Duriau D; Vernel-Pauillac F; Boyer A; Baron-Bodo V; Mallard E; Bartholeyns J; Goxe B; Latour N; Leroy S; Prigent D; Martiat P; Sales F; Laporte M; Bruyns C; Romet-Lemonne JL; Abastado JP; Lehmann F; Velu T
Cancer Immunol Immunother; 2006 Jul; 55(7):819-29. PubMed ID: 16187085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
